Early Stage Products

Research Projects Led Within LFB USA

The proprietary rPRO Technology™ that drives LFB S.A.'s product development enables production of innovative recombinant therapies that are more cost-effective and scalable compared to traditionally produced recombinant therapeutics.

The company’s efforts are focused on developing biosimilars and next-generation biobetter therapeutics that address the limitations of traditional recombinant products without compromising efficacy and safety.

LFB S.A.'s current early stage product candidates are within the areas of oncology and immunology.